McKesson Corporation (NYSE:MCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, November 6th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at

The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on January 2, 2025, to stockholders of record on December 2, 2024. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com an

Believes Nano's Ongoing Value Destruction, Worst-In-Class Corporate Governance and Misallocation of Corporate Resources Warrants Urgent Change in Company's Boardroom Murchinson's Nominees Would Bring Independent Perspectives and Relevant Experience to Restore Shareholders' Confidence in Leadership, Establish Appropriate Capital Allocation Processes, Hold Management Accountable and Oversee Strategy Development and Implementation Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 7.1% of the outstanding shares of Nano Dimension Ltd. (NASDAQ:NNDM) ("Nano" or the "Company"), today annou

McKesson Corporation (NYSE:MCK) will release its second quarter fiscal 2025 financial results after market close on Wednesday, November 6, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide presentation. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, ph

McKesson Corporation (NYSE:MCK) announced today that it has signed an agreement to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. In line with McKesson Corporation's enterprise strategy, this transaction enables McKesson to further focus and prioritize investments to grow its oncology and biopharma services platforms. McKesson Corporation remains fully committed to and confident in the strength of our Canadian distribution and biopharma businesses, delivering solutions to ensure the delivery of better health outcomes. "This transaction marks an important milestone aligned to our enterprise strategy, advancing our strate

Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil

McKesson Corporation (NYSE:MCK) has released its fiscal 2025 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 7th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at i

The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.71 per share of common stock, a 15% increase from $0.62 per share in the prior quarter. The dividend will be payable on October 1, 2024, to stockholders of record on September 2, 2024. "This marks our eighth consecutive annual dividend increase, underscoring the confidence in our business fundamentals and the strength of our balance sheet and free cash flow generation," said Brian Tyler, chief executive officer. "We remain dedicated to our disciplined capital deployment strategy, prioritizing growth and creating value for our shareholders." About McKesson Corporation McKesson Corporat

McKesson Corporation (NYSE:MCK) will release its first quarter fiscal 2025 financial results after market close on Wednesday, August 7, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide presentation. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, ph

McKesson Corporation (NYSE:MCK) announced today that the McKesson board of directors has elected Dr. Deborah Dunsire as a director and member of the Compensation and Talent Committee and Finance Committee, effective June 3, 2024. "We're pleased to welcome Deborah to the McKesson board," said Donald Knauss, McKesson's independent board chair. "She is a highly respected healthcare industry leader with a proven track record of leading large, complex organizations as both a CEO and a board member. Her unique perspective, clinical background and expertise within the pharmaceutical and oncology arenas will add great value to McKesson and its purpose of Advancing Health Outcomes for All®." Dr.

McKesson Corporation (NYSE:MCK) has released its fiscal 2025 second quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, November 6th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at

The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 71 cents per share of common stock. The dividend will be payable on January 2, 2025, to stockholders of record on December 2, 2024. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com an

McKesson Corporation (NYSE:MCK) will release its second quarter fiscal 2025 financial results after market close on Wednesday, November 6, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide presentation. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, ph

McKesson Corporation (NYSE:MCK) has released its fiscal 2025 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, August 7th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at i

The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.71 per share of common stock, a 15% increase from $0.62 per share in the prior quarter. The dividend will be payable on October 1, 2024, to stockholders of record on September 2, 2024. "This marks our eighth consecutive annual dividend increase, underscoring the confidence in our business fundamentals and the strength of our balance sheet and free cash flow generation," said Brian Tyler, chief executive officer. "We remain dedicated to our disciplined capital deployment strategy, prioritizing growth and creating value for our shareholders." About McKesson Corporation McKesson Corporat

McKesson Corporation (NYSE:MCK) will release its first quarter fiscal 2025 financial results after market close on Wednesday, August 7, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide presentation. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, ph

McKesson Corporation (NYSE:MCK) has released its fiscal 2024 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Tuesday, May 7th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at inves

The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of 62 cents per share of common stock. The dividend will be payable on July 1, 2024, to stockholders of record on June 3, 2024. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and rea

McKesson Corporation (NYSE:MCK) will release its fourth quarter and full year fiscal 2024 financial results after market close on Tuesday, May 7, 2024. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. The live webcast will be available on McKesson's Investor Relations website at http://investor.mckesson.com, along with the company's earnings release, financial tables and slide presentation. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care pro

McKesson Corporation (NYSE:MCK) has released its fiscal 2024 third quarter financial results. Results can be accessed on McKesson's Investor Relations website at investor.mckesson.com/financials/quarterly-results. As previously announced, the company will host a live webcast of the earnings conference call for investors today, Wednesday, February 7th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at

McKesson's (NYSE:MCK) short percent of float has fallen 10.63% since its last report. The company recently reported that it has 1.85 million shares sold short, which is 1.43% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.49 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is i

Citigroup analyst Daniel Grosslight maintains McKesson (NYSE:MCK) with a Buy and raises the price target from $620 to $670.

AbbVie Inc (NYSE:ABBV) has petitioned the U.S. Supreme Court to protect its corporate records, arguing that a lower court ruling threatens the confidentiality of attorney communications. The pharmaceutical company is seeking to overturn a decision by the 3rd U.S. Circuit Court of Appeals, stating that filing a sham patent-infringement lawsuit could override attorney-client privilege. The case stems from allegations in the Philadelphia federal court where drug wholesalers, including Cencora Inc (NYSE:COR) (formerly AmerisourceBergen) and McKesson Corporation (NYSE:MCK), claim they were overcharged for the testosterone replacement drug AndroGel. Also Read: AbbVie’s Parkinson’s Disease

Evercore ISI Group analyst Elizabeth Anderson maintains McKesson (NYSE:MCK) with a Outperform and raises the price target from $600 to $660.

The Nasdaq 100 closed higher by around 0.2% on Monday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced. Insider sales should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a selling decision. Below is a look at a few recent notable insider sales. For more, check out Benzinga’s insider transactions platform. Robinhood Markets The Trade: Robinhood Markets, Inc. (NASDAQ:HOOD) Chief Legal Officer Daniel Martin Gallagher Jr sold a total of

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for NVIDIA Corporation (NASDAQ:NVDA) from $130 to $180. Keybanc analyst John Vinh maintained an Overweight rating. NVIDIA shares rose 1.9% to close at $128.20 on Monday. See how other analysts view this stock. Piper Sandler lifted the price target for Robinhood Markets, Inc. (NASDAQ:HOOD) from $18 to $20. Piper Sandler analyst Patrick Moley maintained a Neutral rating. Robinhood shares fell 2.6% to close at $22.09 on Monday. See how other analysts view this stock.

Baird analyst Eric Coldwell maintains McKesson (NYSE:MCK) with a Outperform and raises the price target from $679 to $694.

First, Claudia Post oversaw the safe delivery of eyeballs, kidneys and other organs. Today? Her specialty is cannabis. Most recently, she launched Scarlet Express with financial backing from Ben Sopranzetti, vice chair of the Department of Finance and Economics at Rutgers Business School. The Philadelphia-based startup is a state-approved, closed-loop delivery organization providing discreet, secure and expert cannabis supply chain management nationwide. And Post is the perfect person for this type of venture. A serial entrepreneur, Post launched MOST Consulting Group, a one-stop shop for cannabis marketing and advertising, and founded Diamond Transportation Group, a same-day, ti

McKesson (NYSE:MCK) has outperformed the market over the past 20 years by 7.77% on an annualized basis producing an average annual return of 16.08%. Currently, McKesson has a market capitalization of $75.67 billion. Buying $1000 In MCK: If an investor had bought $1000 of MCK stock 20 years ago, it would be worth $19,674.54 today based on a price of $583.35 for MCK at the time of writing. McKesson's Performance Over Last 20 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and revi

A U.S. bankruptcy judge has approved Rite Aid Corp’s (OTC:RADCQ) restructuring plan, enabling the pharmacy chain to reduce its debt by $2 billion and transfer control to a group of lenders. Rite Aid filed for Chapter 11 bankruptcy in October 2023, following a fiscal year in which it reported $750 million in losses and $24 billion in revenue. During the bankruptcy process, Rite Aid closed hundreds of stores, sold its pharmacy benefit company Elixir, and negotiated settlements with lenders, including its drug distribution partner McKesson Corp (NYSE:MCK) and other creditors. Also Read: Rite Aid Forges Path To Financial Recovery With Major Settlement: Report. Reuters noted the restr

Acquisition enhances McKesson's integrated oncology platform; Florida Cancer Specialists & Research Institute to join The US Oncology Network McKesson Corporation (NYSE:MCK) announced today that it signed a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures). Core Ventures, a business and administrative services organization, was established by Florida Cancer Specialists & Research Institute, LLC (FCS), a leading physician-owned community oncology practice. FCS physicians will continue to retain a minority interest in Core Ventures. McKesson will purchase its controlling interest for approximately $2.49 bil

KORU Medical Systems, Inc. (NASDAQ:KRMD) ("KORU Medical" or the "Company"), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty subcutaneous infusion solutions that improve quality of life for patients, today announced that Edward Wholihan was appointed to the Company's Board of Directors on September 28, 2023 to fill the vacancy that followed the Company's 2023 Annual Meeting of Shareholders. "I am extremely proud to welcome a highly accomplished executive such as Ed to our Board of Directors. He will be a valuable addition and we will benefit from his breadth of experience and success creating shar

NORTHVILLE, Mich., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Gentherm (NASDAQ:THRM), the global market leader of innovative thermal management and pneumatic comfort technologies for the automotive industry and a leader in medical patient temperature management systems, today announced that Dr. Ken Washington has been appointed to the Company's Board of Directors, effective October 2, 2023. Dr. Washington is the Senior Vice President, Chief Technology and Innovation Officer of Medtronic plc (NYSE:MDT), a global healthcare technology company that provides device-based medical therapies and services. He was appointed to this position in June 2023, and he leads innovation and the expansion of technol

Highlights Entrenchment Tactics Taken by the Board Before and Following March Special Meeting Where Shareholders Overwhelmingly Supported Murchinson's Case for Change – Including the Removal of CEO and Chairman Yoav Stern From the Board Puts Forward Proposals to Improve Company's Failed Corporate Governance by Seeking to Remove All Current Directors and Appoint Five New, Experienced and Independent Nominees Murchinson Ltd. (collectively with its affiliates and funds it advises and/or sub-advises, "Murchinson" or "we"), a significant shareholder with approximately 5.9% of the outstanding shares of Nano Dimension Ltd., a company incorporated in Israel (NASDAQ:NNDM) ("Nano Dimension" or th

CALGARY, AB, Jan. 25, 2022 /CNW/ - Comprehensive Healthcare Systems Inc. (TSXV:CHS) (the "Company" or "CHS"), an industry leader in Healthcare Benefits Administration software and services, is pleased to announce the appointment of Chris Cosgrove as the Company's new President and Chief Executive Officer ("CEO") and to its board of directors effective February 1, 2022.  Mr. Cosgrove has 25 years of management and leadership experience in the healthcare technology industry and will replace CHS founder, Dr. Hassan Mohaideen, who will continue in his role as Chairman of the board of directors (the "Board") and be appointed Chief Medical Officer of the Company. "With a proven track record of lea

Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Pam Randhawa was appointed to serve as a member of its board of directors, effective November 1, 2021. Ms. Randhawa is a thought leader within the life sciences sector and an experienced industry executive, with more than 20 years of experience leading public and private companies, ranging from biotech, healthcare and sustainable solutions, through their various stages of growth. Ms. Randhawa will ser